LEIDOS BIOMEDICAL RESEARCH INC

No reported sub-awards as a subcontractor.

• AMERICAN TYPE CULTURE COLLECTION

  UEI KT4MLLHK99V6

  $130.1M

  Subcontracted by this company · 5 sub-awards · latest Oct 29, 2025

  • National Institutes of Health
  • “MANAGEMENT OF THE NCI AT FREDERICK CENTRAL REPOSITORY LOCATIONS.”
  • “SAMPLE ALIQUOTING”
  • “SUBCONTRACTOR SHALL PROVIDE ALIQUOTING SERVICES FOR SERONET SAMPLES ACCORDING TO STANDARD OPERATING PROCEDURES (SOPS) PROVIDED BY THE VACCINE; IMMUNITY AND CANCER DIRECTORATE (VICD) FOR SAMPLE HANDLING, RECEIPT, STORAGE AND ALIQUOTING. SAMPLES WILL BE SENT FROM THE NCI FNR TO THE SUBCONTRACTOR AND THE SUBCONTRACTOR WILL RETURN THE CHILD ALIQUOT SAMPLES TO NCI FNR FOR LONG TERM STORAGE”
• MITCHELL GROUP, INC. (THE)

  UEI C618PGHAWTC6

  $127.5M

  Subcontracted by this company · 20 sub-awards · latest Aug 31, 2026

  • National Institutes of Health
  • “THE SUBCONTRACT SHALL PROVIDE ON-THE-GROUND LEADERSHIP, MANAGEMENT, AND COORDINATION OF PREVAIL’S RESEARCH OPERATIONS, ADMINISTRATION, HUMAN RESOURCES, FINANCIAL, PROGRAMMATIC AND LOGISTICS REQUIREMENTS AND TO BUILD LIBERIAN IN-COUNTRY CAPACITY THAT WILL SUSTAIN THE ONGOING AND FUTURE PREVAIL RESEARCH EFFORTS.”
  • “THE SCOPE OF THIS WORK IS TO RELOCATE THE PREVAIL BIOREPOSITORY, INCLUDING ALL BIOLOGICAL SAMPLES, AND THE PREVAIL RESEARCH LABORATORY, CURRENTLY LOCATED AT LIBR IN CHARLESTOWN, LIBERIA, TO THE JFKMC IN MONROVIA, LIBERIA. ADDITIONALLY, THIS SCOPE INCLUDES THE OPERATION AND MAINTENANCE OF THE INFRASTRUCTURE WITHIN THE BIOREPOSITORY AND WAREHOUSE AT JFKMC. THE SUBCONTRACTOR SHALL PROVIDE ALL NECESSARY EQUIPMENT, LABOR AND SUPPLIES NEEDED TO MOVE BIOLOGICAL SAMPLES, STAFF, EQUIPMENT, FURNITURE, SUPPLIES AND ANY OTHER PREVAIL PROPERTY, CURRENTLY LOCATED AT LIBR, TO SUPPORT THE BIOREPOSITORY AND RESEARCH LABORATORY, AND ITS FUNCTIONALITY TO JFKMC.”
  • “THE SUBCONTRACTOR SHALL PROVIDE ALL RESOURCES REQUIRED TO MAINTAIN THE UCRC CORE CLINICAL RESEARCH INFRASTRUCTURE RESEARCH PLATFORM CLINICAL RESEARCH CENTER AND RESEARCH LAB FACILITIES. CONTINUITY OF SERVICE IS IMPERATIVE. THE SUBCONTRACTOR WILL BE TASKED TO SUPPORT ALL ASPECTS OF THE UCRC RESEARCH PLATFORM, INCLUDING, BUT NOT LIMITED TO: PROGRAM COORDINATION, HUMAN RESOURCES MANAGEMENT, ACCOUNTING AND FINANCIAL MANAGEMENT, SUPPLY CHAIN PROCUREMENT AND LOGISTICS, CLINICAL RESEARCH SITE OPERATIONS, FACILITIES SITE AND INFORMATION TECHNOLOGY (IT) MANAGEMENT, TRAVEL SUPPORT, MEETINGS, CONFERENCES, TRAININGS AND WORKSHOPS PLANNING AND FACILITATION, COMMUNITY ENGAGEMENT, REGULATORY AND ETHICS, ADMINISTRATIVE SUPPORT, REPOSITORY MANAGEMENT, AND PROVIDE FOR AN ORDERLY TRANSITION CLOSEOUT. THE SUBCONTRACTOR SHALL IMPLEMENT PROGRAMMATIC DETERMINATIONS MADE BY THE UCRC GOVERNANCE, ADMINISTRATIVE MANAGEMENT, AND OPERATIONAL STRUCTURE AND AT THE DIRECTION OF LEIDOS BIOMED. THE SUBCONTRACTOR SHALL ALSO SUPPORT OTHER ASSOCIATED NIAID, USTTB, AND COLLABORATOR, AS REQUESTED.”
• ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

  UEI C8H9CNG1VBD9

  $113.9M

  Subcontracted by this company · 2 sub-awards · latest Nov 1, 2024

  • National Institutes of Health
  • “SUBCONTRACTOR SHALL CONTINUE TO ADDRESS UNMET NEEDS IN SARS-COV-2 SEROLOGICAL TESTING AND RESEARCH THROUGH INVESTIGATION OF CHARACTERISTICS OF THE IMMUNE RESPONSE THAT CORRELATE WITH PROTECTION FROM INFECTION OR SEVERE DISEASE, WITH A FOCUS ON CANCER PATIENTS. LONGITUDINAL STUDIES SHALL CONTINUE ONLY IN THE MULTIPLE MYELOMA COHORT; IN HEMATOLOGICAL CANCER TRANSPLANT RECIPIENTS (WITH AND WITHOUT HIV)AND WITH HEALTHY CONTROLS TO ACHIEVE MATCHED TIME POINTS. THIS WORK WILL BE CONDUCTED IN PARTNERSHIP WITH SERONET; INCLUDING THE FNLCR SEROLOGY LABORATORY; AND THE SSC; TO DEVELOP AND PROVIDE REAGENTS AND STANDARDS TO THE SEROLOGY COMMUNITY ONCE GENERATED AND QUALIFIED. TECHNOLOGY DEVELOPMENT INCLUDES CONDUCTING A PILOT TO ADDRESS THE POSSIBILITY OF INCREASED INCIDENCE OF CANCER DUE TO SARS-COV-2 AS WELL AS COLLECTIONS FROM NOVEL VACCINE RECIPIENTS.”
  • “THE OBJECTIVE OF THE FOLLOWING PUBLIC HEALTH INVESTIGATIONS IS TO DETERMINE THE ANTI-SARS-COV-2 ANTIBODY LEVELS AND SARS-COV-2 TOTAL NEUTRALIZING ANTIBODY PREVIOUSLY EXPOSED TO SARS-COV-2 AND/OR VACCINATED WITH CURRENT COVID-19 VACCINES, USING VALIDATED SARS-COV-2 SEROLOGICAL ASSAYS WITH EVIDENCE OF HIGH SPECIFICITY AND SENSITIVITY. STUDY 1: IN THE NCI COVID-19 IN CANCER PATIENTS STUDY (NCCAPS) PATIENTS, THE PLAN IS TO INVESTIGATE LONGITUDINAL ANTIBODY RESPONSE TO SARS-COV-2 INFECTION AND VACCINATION. STUDY 2: IN THE NCI CLINICAL CENTER STUDY, THE OBJECTIVE IS TO INVESTIGATE THE SAFETY AND IMMUNOGENICITY OF THE COVID-19 VACCINE (MRNA-1273) IN PARTICIPANTS WITH HEMATOLOGIC MALIGNANCIES AND VARIOUS REGIMENS OF IMMUNOSUPPRESSION AND IN PARTICIPANTS WITH SOLID TUMORS ON PD1/PDL1 INHIBITOR THERAPY, INCLUDING BOOSTER DOSES OF VACCINE. STUDY 3: IN THE CHILDREN'S ONCOLOGY GROUP (COG) STUDY, THE OBJECTIVE IS TO EVALUATE IMMUNOLOGIC RESPONSE FOLLOWING COVID-19 VACCINATION IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH CANCER.”
• THE UNIVERSITY OF CHICAGO

  UEI ZUE9HKT2CLC9

  $21.8M

  Subcontracted by this company · 4 sub-awards · latest Aug 31, 2025

  • National Institutes of Health
  • “GDC HARDWARE REFRESH”
  • “GDC IMPLEMENTATION”
• FISHER BIOSERVICES INC

  UEI LB4PCGLSJ9E6

  $11.1M

  Subcontracted by this company · 1 sub-award · latest Aug 6, 2024

  • National Institutes of Health
  • “PROVIDE BIOLOGICAL, CGMP CELL BANK STORAGE, ANALYTICAL SERVICES AND CLINICAL MANAGEMEN”
• FRED HUTCHINSON CANCER CENTER

  UEI TJFZLPP6NYL6

  $10.9M

  Subcontracted by this company · 2 sub-awards · latest Dec 1, 2025

  • National Institutes of Health
  • “IMPLEMENT, OPERATIONALIZE, AND MAINTAIN INFRASTRUCTURE TO SUPPORT MDNET MYELOMATCH ASSAYS AND ANALYSES; CYTOGENETIC ANALYSIS OF MDNET MYELOMATCH SPECIMENS; AND NCI MYELOID ASSAY (GENEXUS MYELOID NGS) ANALYSIS OF MDNET MYELOMATCH SPECIMENS.”
  • “THE SCOPE OF THIS WORK IS TO ADAPT THE IO-MASTER (IO-1, IO-2, AND IO-3) AND IO-4 ASSAYS FOR PARALLEL REACTION MONITORING. THE WORK SHALL INCLUDE CELL LINE AND PEPTIDE TESTING, DESIGN AND PRELIMINARY OPTIMIZATION OF PRM ASSAYS FOR CELL LINES, CLINICAL SAMPLE PREPARATION, OPTIMIZATION OF PRM ASSAYS FOR CLINICAL SAMPLES, AND VALIDATING THE PRM ASSAYS. UPDATES WILL BE PROVIDED TO THE LEIDOS BIOMEDICAL RESEARCH, INC. (LEIDOS BIOMED) TECHNICAL PROJECT MANAGER (TPM) AT MONTHLY TELECONFERENCES TO ENSURE THE WORK IS ON SCHEDULE AND MEETS CPTAC QUALITY STANDARDS. SEE CPTAC DCC WEBSITE FOR CPTAC STANDARD DETAILS: HTTPS://CPTAC-DATA-PORTAL.GEORGETOWN.EDU/CPTAC/STUDY/DISCLAIMER.”
• REGENTS OF THE UNIVERSITY OF MINNESOTA

  UEI KABJZBBJ4B54

  $8.3M

  Subcontracted by this company · 1 sub-award · latest Jan 14, 2025

  • National Institutes of Health
  • “MS4 OPT2 - STUDY 3”
• VANDERBILT UNIVERSITY

  UEI GTNBNWXJ12D5

  $5.6M

  Subcontracted by this company · 2 sub-awards · latest Nov 5, 2025

  • National Institutes of Health
  • “MYC/MAX PROJECT”
• GENERAL DYNAMICS INFORMATION TECHNOLOGY, INC.

  UEI SMNWM6HN79X5

  $4.7M

  Subcontracted by this company · 1 sub-award · latest Oct 9, 2025

  • National Institutes of Health
  • “THE SCOPE OF THIS STATEMENT OF WORK IS TO SUPPORT ALL ACTIVITIES IN THE DEVELOPMENT OF THE CLINREGS PROJECT AS OUTLINES BELOW. REQUIRED SUPPORT FOR THE CLINREGS PROJECT WILL INVOLVE SEVERAL DISTINCT ELEMENTS AND AREAS OF ACTIVITY, INCLUDING: 1) CONTENT DEVELOPMENT AND MAINTENANCE; 2) GOVERNANCE; STAKEHOLDER ENGAGEMENT; AND 3) WEBSITE DEVELOPMENT AND MAINTENANCE. THE SUBCONTRACTOR WILL SUPPORT BOTH CONTENT DEVELOPMENT AND THE TECHNICAL REQUIREMENTS OF WEBSITE DEVELOPMENT AND MAINTENANCE.”
• THE EMMES COMPANY, LLC

  UEI NBQCBJ6FXBU4

  $4.1M

  Subcontracted by this company · 2 sub-awards · latest Aug 3, 2026

  • National Institutes of Health
  • “IN SUPPORT OF THE NIAID DMID H5N1 VACCINE CLINICAL TRIAL, LEIDOS BIOMED IS TASKED WITH THE MANAGEMENT OVERSIGHT AND CONDUCT OF THE H5N1 VACCINE CLINICAL TRIAL AND SEEKS TO CONTRACT WITH AN ORGANIZATION WITH THE CAPABILITIES TO PROVIDE DATA MANAGEMENT AND STATISTICAL ANALYSIS SUPPORT TO THE H5N1 VACCINE TRIAL AS OUTLINED IN THIS STATEMENT OF WORK. THE DATA MANAGEMENT AND STATISTICAL ANALYSIS ORGANIZATION SHOULD HAVE EXPERIENCE WITH INVESTIGATION NEW DRUG (IND) TRIALS, HAVE ALL THE NECESSARY REGULATORY REPORTING EXPERIENCE (PREFERABLY INFECTIOUS DISEASE), AND USE A VALIDATED 21 CODE OF FEDERAL REGULATIONS (CFR) PART 11 COMPLIANT SYSTEMS.”
• Allucent Government Services (US) LLC

  UEI C7DJDL6EZT94

  $3.3M

  Subcontracted by this company · 1 sub-award · latest Oct 15, 2024

  • National Institutes of Health
  • “THE OBJECTIVE IS TO PROVIDE PROJECT AND PROGRAM MANAGEMENT, PROTOCOL DESIGN AND DEVELOPMENT, CLINICAL RESEARCH SITE OPERATIONS, DATABASE BUILD AND MANAGEMENT SERVICES, AND REPORTING TO SUPPORT A PHASE 1 BA/DDI STUDY WITH A NOVEL ANTIVIRAL.”
• UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

  UEI D3LHU66KBLD5

  $2.5M

  Subcontracted by this company · 1 sub-award · latest Feb 4, 2026

  • National Institutes of Health
  • “COMPLETE THE HT-ATAC-SEQ HIGH THROUGHPUT SCREEN USING THIS ASSAY AND VALIDATE HIT MOLECULES.”
• EMORY UNIVERSITY

  UEI S352L5PJLMP8

  $2.4M

  Subcontracted by this company · 2 sub-awards · latest Nov 30, 2023

  • National Institutes of Health
  • “MS7-CHRCT & CNFRM TESTING”
  • “MS1 DMID COVAIL OVERARCH”
• CHILDREN'S HOSPITAL LOS ANGELES

  UEI DVL1CMRMWRN9

  $1.9M

  Subcontracted by this company · 2 sub-awards · latest Nov 12, 2025

  • National Institutes of Health
  • “CONDUCTING CLINICAL ASSAYS FOR MYELOMATCH TRIALS.”
  • “SUBCONTRACTOR WILL PROVIDE EXPERT SUPPORT TO THE FNLCR, NCI PROGRAM LEADERSHIP, MDNET PROJECT TEAMS, AND THE NCTN GROUPS FOR THE MDNET MYELOMATCH PRECISION MEDICINE INITIATIVE.”
• THERMO ELECTRON NORTH AMERICA LLC

  UEI CMBPHDRMCS51

  $1.7M

  Subcontracted by this company · 1 sub-award · latest Nov 17, 2023

  • National Institutes of Health
  • “CAPITAL EQUIPMENT”

No active exclusion on record (checked Nov 14, 2026).

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.

No confirmed match on the Consolidated Screening List (screened Nov 14, 2026).

The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.